Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.
Lovell, Daniel J
Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. [electronic resource] - Arthritis & rheumatology (Hoboken, N.J.) Oct 2015 - 2759-70 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
2326-5205
10.1002/art.39234 doi
Abatacept--adverse effects
Activities of Daily Living--psychology
Adolescent
Antirheumatic Agents--adverse effects
Arthritis, Juvenile--drug therapy
Child
Double-Blind Method
Female
Humans
Longitudinal Studies
Male
Psychology
Quality of Life--psychology
Self Report
Surveys and Questionnaires
Time Factors
Treatment Outcome
Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. [electronic resource] - Arthritis & rheumatology (Hoboken, N.J.) Oct 2015 - 2759-70 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
2326-5205
10.1002/art.39234 doi
Abatacept--adverse effects
Activities of Daily Living--psychology
Adolescent
Antirheumatic Agents--adverse effects
Arthritis, Juvenile--drug therapy
Child
Double-Blind Method
Female
Humans
Longitudinal Studies
Male
Psychology
Quality of Life--psychology
Self Report
Surveys and Questionnaires
Time Factors
Treatment Outcome